UBS Group
GYRE icon

UBS Group’s Gyre Therapeutics GYRE Stock Holding History

UBS Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-28
Closed -$59K – 9013
2014
Q4 		$59K Buy
+28
New +$53.9K ﹤0.01% 6276

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's GYRE Position: Q2 2026 in Review

UBS Group reduced its Gyre Therapeutics (GYRE) stake by 11% in Q2 2026, selling an estimated $15.8K and leaving 18,763 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #7060.

UBS Group first reported a position in GYRE in Q4 2015 and has held it in 37 quarters since. The position peaked at $1.12M in Q4 2015. 59 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • UBS Group held 18,763 shares of Gyre Therapeutics worth $124K as of Q2 2026.
  • UBS Group sold 2,324 Gyre Therapeutics shares in Q2 2026, an estimated $15.8K.
  • Gyre Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7060 holding.
  • UBS Group first reported a position in Gyre Therapeutics in Q4 2015 and has held it in 37 quarters since.
  • UBS Group's Gyre Therapeutics position peaked at $1.12M in Q4 2015.
  • 59 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.